1. Home
  2. TENX vs INDP Comparison

TENX vs INDP Comparison

Compare TENX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$12.46

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.04

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
INDP
Founded
1967
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
INDP
Price
$12.46
$2.04
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
216.0K
35.5K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$1.65
52 Week High
$14.22
$47.60

Technical Indicators

Market Signals
Indicator
TENX
INDP
Relative Strength Index (RSI) 75.96 38.85
Support Level $10.40 $2.39
Resistance Level $14.22 $2.94
Average True Range (ATR) 0.90 0.20
MACD 0.26 0.00
Stochastic Oscillator 67.77 2.20

Price Performance

Historical Comparison
TENX
INDP

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: